A Clinical Study of Allogeneic Human Adipose-derived Mesenchymal Progenitor Cell Exosomes (haMPC-Exos) Nebulizer for the Treatment of Carbapenem-resistant Gram-negative Bacilli-induced Pulmonary Infection
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Allogeneic-adipose-derived-mesenchymal-stem-cell-therapy-AbelZeta-Pharma (Primary)
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Therapeutic Use
- 22 Jul 2024 Planned End Date changed from 1 Jul 2023 to 1 Mar 2025.
- 22 Jul 2024 Planned primary completion date changed from 1 May 2023 to 1 Dec 2024.
- 21 Jul 2024 Status changed from recruiting to suspended. (Due to the COVID-19 pandemic, patient enrollment was slower than expected. After enrolling 26 patients, the trial was suspended as our partner company stopped producing haMPC-Exos)